To Abreviate or not to Abreviate [Regulatives / Guidelines]

posted by GSTATS Homepage – India, 2010-05-27 20:30 (5502 d 00:28 ago) – Posting: # 5389
Views: 17,228

Dear KR,

As per my understanding, if i am not wrong FDA wants you to conduct a three way crossover study with two doses of reference and then fitting an Emax model (as given in recommendation) for reference which will provide estimated values of parameters used in model.
Put those estimated values again in model for test product as response and find relative bioavailability (F) of test with respect to reference.

And 90% confidence intervals for "F" can be calculated by repetitive sampling method using Bootstrap procedure.

I hope this will help you.

Regards,
GSTATS
http://gstatsolutions.com/Medical%20Research.html

Let Noble Thoughts come from Every Side: RIG VEDA

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
33 visitors (0 registered, 33 guests [including 10 identified bots]).
Forum time: 20:59 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5